psychogenic

(redirected from Psychogenics)
Also found in: Dictionary, Thesaurus, Medical.

psychogenic

Psychol (esp of disorders or symptoms) of mental, rather than organic, origin

psychogenic

[¦sī·kō¦jen·ik]
(medicine)
Of psychic origin.
References in periodicals archive ?
PsychoGenics is a provider of vivo phenotypic drug discovery.
We are excited to enter into this alliance with Dr Kehr further cementing PsychoGenics as a leading CNS company with in vivo and in vitro drug evaluation capabilities.
PsychoGenics is a leader in preclinical behavioral neurobiology.
Emer Leahy, President and CEO of PsychoGenics said, "We are excited about this collaboration and look forward to working with AstraZeneca's scientific team.
We are eager to start our work with PsychoGenics in this important area of research, and we are excited to be able to access their innovative technologies and to leverage their expertise in neurobiology.
PsychoGenics has developed proprietary high-throughput drug discovery platforms that combine expertise in behavioral neurobiology with the power of robotics, bioinformatics and computer vision to discover the next generation of neuropsychiatric drugs.
David is joining PsychoGenics at an important juncture in our Company's evolution as we expand our drug discovery capabilities and explore interesting mechanisms for clinical development such as spin-off entities.
I look forward to advancing the clinical development of PsychoGenics' numerous discoveries through partnerships, through interesting corporate structures such as Psylin Neurosciences, and within PsychoGenics itself.
Afraxis developed ESP to characterize potential drug candidates for our own discovery program in Fragile X syndrome, and now partnering with PsychoGenics allows us to offer the technology to other companies pursuing CNS drug discovery.
I look forward to my contribution as an advisor to PsychoGenics, a stimulating company with a unique and innovative approach to drug discovery", commented Dr.
We are extremely excited about John's addition to our SAB", explained Dr Eric Nestler, Scientific co-founder and Chairman of PsychoGenics' Scientific Advisory Board, "John's considerable experience and expertise in drug discovery and development will be of great value to PsychoGenics as it expands its internal and partnered drug discovery programs".
PsychoGenics is a leader in preclinical behavioral neurobiology and a provider of customized and innovative solutions for central nervous system (CNS) drug discovery.